Targeting T cell dysfunction in glioblastoma using new antibody treatments
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
['FUNDING_R01'] · YALE UNIVERSITY · NIH-11005755
This study is looking at how to boost the immune system in people with glioblastoma, a type of brain cancer, by using two special antibodies to help T cells fight the tumor better, and we’ll be keeping a close eye on how these treatments work.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-11005755 on ClinicalTrials.gov |
What this research studies
This research investigates how to improve the immune response in patients with glioblastoma, a type of brain cancer, by targeting specific proteins that inhibit T cell function. The study will test a combination of two antibodies, AB154 and AB122, to see if they can enhance the effectiveness of the immune system against the tumor. Patients will be closely monitored to understand how these treatments affect T cell activity and tumor response. The goal is to identify new therapeutic strategies that could lead to better outcomes for glioblastoma patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who have not responded well to existing treatments.
Not a fit: Patients with other types of brain tumors or those who have already received extensive treatment for glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in targeting immune checkpoints in various cancers, suggesting that this approach may also be effective in glioblastoma.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAFLER, DAVID A. — YALE UNIVERSITY
- Study coordinator: HAFLER, DAVID A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer